- |||||||||| Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
Enrollment change: AVINALI: Inhaled ZYESAMI (clinicaltrials.gov) - Jun 8, 2021 P2/3, N=144, Recruiting, N=288 --> 144
- |||||||||| Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
Enrollment open, Phase classification, Trial initiation date: Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS (clinicaltrials.gov) - May 13, 2021 P2, N=82, Recruiting, N=288 --> 144 Not yet recruiting --> Recruiting | Phase classification: P1 --> P2 | Initiation date: Jan 2021 --> May 2021
- |||||||||| Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
"will begin by testing Zyesami, a formulation of aviptadil acetate, produced by @NeuroRxPharma, Wilmington, Delaware, and the antiviral remdesivir (Veklury), developed by @GileadSciences" (Twitter) - Apr 22, 2021
- |||||||||| Zyesami IV (aviptadil intravenous) / Relief Therap, NRx Pharma
Enrollment open: TESICO: ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (clinicaltrials.gov) - Apr 18, 2021 P3, N=640, Recruiting, Not yet recruiting --> Recruiting | Phase classification: P1 --> P2 | Initiation date: Jan 2021 --> May 2021 Not yet recruiting --> Recruiting
- |||||||||| Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
$rlf $rlftf #aviptadil (Twitter) - Mar 20, 2021
- |||||||||| Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NeuroRx
$RLFTF #RLF-100 Let’s go baby! (Twitter) - Mar 16, 2021
- |||||||||| Zyesami IV (aviptadil intravenous) / Relief Therap, NRx Pharma
Trial completion: COVID-AIV: Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (clinicaltrials.gov) - Feb 25, 2021 P2/3, N=196, Completed, Available data from blood gases showed stark increases in PaO2:FiO2 ratio after the 2nd dose (Median increase = 92.5, IQR = 74) and at 24 hours after the 3rd dose (Median increase over baseline 84.5, IQR = 110). Active, not recruiting --> Completed
- |||||||||| Zyesami inhalation (aviptadil) / Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma
Enrollment open: AVINALI: Inhaled ZYESAMI (clinicaltrials.gov) - Feb 21, 2021 P2/3, N=288, Recruiting, Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| aviptadil (DK-1000) / Relief Therap, United Therapeutics, Seren Clinical, NeuroRx
What about RLF-100? (Twitter) - Jan 14, 2021
- |||||||||| aviptadil (DK-1000) / Relief Therap, United Therapeutics, Seren Clinical, NeuroRx
One exists....aviptadil (Twitter) - Dec 23, 2020
- |||||||||| aviptadil (DK-1000) / Relief Therap, United Therapeutics, Seren Clinical, NeuroRx
#AviptadilStopsCovid #RLF100 (Twitter) - Dec 6, 2020
|